Drugs / SHR-2010
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05398510 | Jun 2022 → Mar 2023 | IgA glomerulonephritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05847920 | Jun 2023 → Jan 2025 | IgA glomerulonephritis | Guangdong Hengrui Pharmaceutical Co., Ltd | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-2010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05847920 ↗ |
| Action | Inhibit | “SHR-2010 demonstrated a notable inhibitory effect on lectin pathway” PMID 40297949 ↗ May 2025 |
| Route | Intravenous | “32 via intravenous drip” PMID 40297949 ↗ May 2025 |